title: Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.
abstract: The tumor cells in ALK-positive lymphoma ("ALKoma") usually express the product of the NPM-ALK chimeric gene, generated by the t(2;5) chromosomal translocation. However, 10% to 20% of ALK-positive lymphomas express ALK fusion protein(s) other than NPM-ALK, and in this report, we describe the immunohistologic and clinicopathologic features of 15 such cases. The absence of the NPM-ALK fusion gene was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) in 8 cases and by fluorescence in situ hybridization (FISH) analysis in a further 2 cases. In each case, ALK staining was restricted to the cytoplasm and the N-terminus of NPM to the nucleus (contrasting with lymphomas expressing NPM-ALK in which cytoplasmic as well as nuclear labeling is seen). However, in the course of screening 53 ALK-positive lymphomas, 2 biopsies were found that had a "cytoplasm-only" ALK staining pattern but that nevertheless were shown to carry the (2;5) (by NPM staining and RT-PCR). The 15 cases resembled typical NPM-ALK-positive lymphomas in that all were of T or null phenotype, usually occurred in young male patients, and frequently presented with advanced disease associated with systemic symptoms and extranodal involvement. Moreover, their prognosis was excellent and indistinguishable from that of classical t(2;5)-positive tumors, but was clearly different from that of ALK-negative anaplastic large-cell lymphomas. These results suggest that lymphomas carrying variants of the NPM-ALK fusion protein can be detected by immunostaining for ALK and NPM and also that they can be grouped with classical t(2;5)-positive tumors as a single entity (ALK-positive lymphoma or "ALKoma") that shows a better prognosis than ALK-negative anaplastic large-cell lymphoma.
authors.affiliation: Institute of Hematology, University of Perugia, Perugia, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Falini
authors.forename: K
authors.initials: K
authors.lastname: Pulford
authors.forename: A
authors.initials: A
authors.lastname: Pucciarini
authors.forename: A
authors.initials: A
authors.lastname: Carbone
authors.forename: C
authors.initials: C
authors.lastname: De Wolf-Peeters
authors.forename: J
authors.initials: J
authors.lastname: Cordell
authors.forename: M
authors.initials: M
authors.lastname: Fizzotti
authors.forename: A
authors.initials: A
authors.lastname: Santucci
authors.forename: P G
authors.initials: PG
authors.lastname: Pelicci
authors.forename: S
authors.initials: S
authors.lastname: Pileri
authors.forename: E
authors.initials: E
authors.lastname: Campo
authors.forename: G
authors.initials: G
authors.lastname: Ott
authors.forename: G
authors.initials: G
authors.lastname: Delsol
authors.forename: D Y
authors.initials: DY
authors.lastname: Mason
mesh_terms: D000293:Adolescent; D000077548:Anaplastic Lymphoma Kinase; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008223:Lymphoma / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic
chemical_list: C107023:p80(NPM-ALK) protein; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases